Navigation Links
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Date:2/11/2008

ous adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the marketing and development of Zevalin, or the development of XYOTAX and pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin, XYOTAX, and pixantrone in particular including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, XYOTAX, and pixantrone. In addition, we ma
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
2. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
3. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
4. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
5. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
6. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
7. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
8. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
9. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
10. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... Below is,updated text of Shire plc,s conference call notification. ... been updated from an earlier,release. Shire PLC (LSE: ... will announce third quarter 2007 earnings on,Thursday 1 November ... 12:00 GMT / 08:00 ET, Investor meeting and ...
... (Nasdaq: ARNA ) today reported financial results for ... in the third quarter of 2007 were $5.0 million, ... Total revenues in the first,nine months of 2007 were ... months of 2006. Revenues in the first nine months ...
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced that ... on Wednesday, October 24,2007 after the market closes. The ... 5:00 p.m. ET, which will be open to the ... company will review,the financial results and discuss other business ...
Cached Biology Technology:Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast 2
(Date:8/31/2014)... the greatest challenges in modern medicine is developing drugs ... minimal toxicity and side-effects to the patient. Such properties ... drug molecule. Ideally, the drug should have a shape ... that it binds it with high specificity. Publishing in ... synthetic amino acid that can impact the 3D structure ...
(Date:8/31/2014)... malaria diagnosis has changed very little. After taking a blood ... a glass slide, stains it with a special dye, and ... the disease. This approach gives an accurate count of how ... of disease severity but is not ideal because there ... the Singapore-MIT Alliance for Research and Technology (SMART) has now ...
(Date:8/29/2014)... recently, little has been known about what genetic changes ... of scientists, one of whom is a University of ... that genes controlling the development of the brain and ... The study was published Aug. 28 in Science ... is online at http://www.sciencemag.org/ ., The domestication of ...
Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3A new way to diagnose malaria 2A new way to diagnose malaria 3New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... CAMBRIDGE, Mass. (March 16, 2011) Renowned cancer researchers ... Douglas Hanahan, Director of the Swiss Institute for Experimental ... "Hallmarks of Cancer," which has influenced the study of ... a decade. Published in January 2000, their original ...
... Global Change Biology Bioenergy proposes a new method ... in bioenergy systems. CO 2 emissions resulting from ... and environmental impact studies because bioenergy is carbon- and climate- ... combustion are sequestered by growing biomass. Its climate impact has ...
... Mass., March 16, 2011 The nutritional content of ... as owner,s perceptions about them, according to a study ... School of Veterinary Medicine at Tufts University. ... humans and petschange with aging, the Association of American ...
Cached Biology News:Whitehead scientist helps revisit 'Hallmarks of Cancer' 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 3Wide variety in nutritional content found in 'senior' dog foods 2Wide variety in nutritional content found in 'senior' dog foods 3
... COOLSCOPE is an integrated digital microscope and ... computer, equipment setup, optical adjustment or software ... innovative technology, COOLSCOPE combines simplicity and advanced ... COOLSCOPE offers simultaneous viewing of a macro ...
... kit provides complete components including positive ... detection of DNA fragmentation in cultured ... of BrdU in the procedure provides ... methods. Results can be analyzed by ...
... Life Science LAS-3000 imaging system combines ... simplified user interface, providing significantly improved ... of modularities. The system is especially ... perfect standard system for Western blotting ...
... Science LAS-3000mini is a compact image ... applications, and the perfect standard system ... LAS-3000 provides significantly improved system sensitivity ... calibration standards validate that Fujis LAS-3000 ...
Biology Products: